WO2005039614A3 - Omega interferon for the treatment of hiv/aids, cancer and human and veterinary asthma - Google Patents

Omega interferon for the treatment of hiv/aids, cancer and human and veterinary asthma Download PDF

Info

Publication number
WO2005039614A3
WO2005039614A3 PCT/OA2004/000003 OA2004000003W WO2005039614A3 WO 2005039614 A3 WO2005039614 A3 WO 2005039614A3 OA 2004000003 W OA2004000003 W OA 2004000003W WO 2005039614 A3 WO2005039614 A3 WO 2005039614A3
Authority
WO
WIPO (PCT)
Prior art keywords
human
diseases
asthma
aids
treatment
Prior art date
Application number
PCT/OA2004/000003
Other languages
French (fr)
Other versions
WO2005039614A2 (en
Inventor
Nee Bellet Anne Brigitte Koung
Zollo Paul Henri Amvam
Jean Yves Gauchet
Original Assignee
Nee Bellet Anne Brigitte Koung
Zollo Paul Henri Amvam
Jean Yves Gauchet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nee Bellet Anne Brigitte Koung, Zollo Paul Henri Amvam, Jean Yves Gauchet filed Critical Nee Bellet Anne Brigitte Koung
Publication of WO2005039614A2 publication Critical patent/WO2005039614A2/en
Publication of WO2005039614A3 publication Critical patent/WO2005039614A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The invention relates to a pharmaceutical composition with a whole immunotherapeutic activity, proven at 89 %, activating both cellular and humoral immunity in human and veterinary medicine, the protocol for use and therapeutic indications thereof. Said pharmaceutical composition, once subcutaneously and intramuscularly injected into well-specified sites of the lymphoid system and ganglionic areas of the sick organism, has a both cellular and humoral, progressive and perennial immunotherapeutic effect. The pharmaceutical formula of our composition is based on lymphocytic omega interferon, associated with vasodilator, antioxidant, anticoagulant and corticosteroid agents. The synergistic action of the cytokines and agents is provided for treatment of: chronic viral diseases, specifically HIV1, HIV2, AIDS and viral hepatitis; intracellular parasitic bacteria diseases: bacterial or trypanosomiasis leishmaniasis, tuberculosis, syphilis, chlamydia and mycoplasma; chronic allergic disorders: asthma; mesodermal and lymphoid cancer processes. Our invention and the mode of application thereof are suitable for treating said diseases both in human and veterinary medicine.
PCT/OA2004/000003 2003-10-29 2004-10-10 Omega interferon for the treatment of hiv/aids, cancer and human and veterinary asthma WO2005039614A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
OA1200300287A OA12835A (en) 2003-10-29 2003-10-29 Interferon omega against HIV / AIDS, cancer and human and veterinary asthma.
OA1200300287 2003-10-29

Publications (2)

Publication Number Publication Date
WO2005039614A2 WO2005039614A2 (en) 2005-05-06
WO2005039614A3 true WO2005039614A3 (en) 2005-07-14

Family

ID=34511360

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/OA2004/000003 WO2005039614A2 (en) 2003-10-29 2004-10-10 Omega interferon for the treatment of hiv/aids, cancer and human and veterinary asthma

Country Status (2)

Country Link
OA (1) OA12835A (en)
WO (1) WO2005039614A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016021602A1 (en) * 2014-08-04 2016-02-11 日東電工株式会社 Liquid immunity induction-promoting composition and vaccine pharmaceutical composition that include thrombosis treatment drug

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003031566A2 (en) * 2001-07-20 2003-04-17 Human Genome Sciences, Inc. Keratinocyte derived interferon
US20030143197A1 (en) * 2001-11-09 2003-07-31 Moran S. Mark Method for treating diseases with omega interferon

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003031566A2 (en) * 2001-07-20 2003-04-17 Human Genome Sciences, Inc. Keratinocyte derived interferon
US20030143197A1 (en) * 2001-11-09 2003-07-31 Moran S. Mark Method for treating diseases with omega interferon

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HORTON HOLLY M ET AL: "Antitumor effects of interferon-omega: In vivo therapy of human tumor xenografts in nude mice", CANCER RESEARCH, vol. 59, no. 16, 15 August 1999 (1999-08-15), pages 4064 - 4068, XP002319688, ISSN: 0008-5472 *
KUNZI MYRIAM S ET AL: "Role of interferon-stimulated gene ISG-15 in the interferon-omega-mediated inhibition of human immunodeficiency virus replication", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, vol. 16, no. 11, 1996, pages 919 - 927, XP008043880, ISSN: 1079-9907 *

Also Published As

Publication number Publication date
OA12835A (en) 2006-09-15
WO2005039614A2 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
SG52443A1 (en) Methods and compositions for the treatment of disease with interferon while reducing sid effects
TW371660B (en) Therapeutic nucleosides a purine carbocyclic nucleosides for treatment of HIV and HBV infections
HUP0100092A2 (en) Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
HK1084862A1 (en) Use of omega interferon in the manufacturing of a medicament for treating viral disease in a warm-blooded animal subject
HUP0300027A2 (en) Nucleoside analogs with carboxamidine modified monocyclic base and process for their use
EP2356990A3 (en) Liposome treatment of viral infections
MY127670A (en) Pegylated interferon alfa-ccr5 antagonists combination hiv therapy
WO2005039614A3 (en) Omega interferon for the treatment of hiv/aids, cancer and human and veterinary asthma
Mor et al. Enhancement of growth of Mycobacterium lepraemurium in macrophages by gamma interferon
ATE316379T1 (en) OXYHUMIC ACID AND ITS USE IN THE TREATMENT OF VARIOUS DISORDERS
WO2005058237A3 (en) Treatment of aids
WO2000017361A3 (en) Interferon-epsilon
WO2005058248A3 (en) A method of treating hiv infection in atazanavir resistant patients using a combination of atazanavir and another protease inhibitor
RU2423143C2 (en) Method of treating patient with chronic brucellosis
YU66099A (en) Transdermal system for administration of medicaments and use of therapeutic mixtures in the production of drugs for treatment of virus and microbe infections and harmful syndromes
WO2022125378A3 (en) Combination therapy
WO2001079289A3 (en) Human interferon, zinf2
Mascolini Six days inside the beltway--and most AIDS clinicians still come out smiling
Simmons Interleukin-2 for the treatment of HIV infection
TH70235A (en) Methods for treating hepatitis infection C. In patients whose treatment has failed.
TH70146A (en) Methods for treating hepatitis C infection in patients who have failed treatment
MY119359A (en) Use of consensus interferon for reducing the side effects of interferon treatment in viral hepatitis.
UA38388A (en) METHOD OF TREATMENT OF Mumps
TH23210A (en) "Plavin derivatives are used as antiviral agents"

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
122 Ep: pct application non-entry in european phase

Ref document number: 04793741

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: CONSTATATION DE LA PERTE D UN DROIT CONFORMEMENT A LA REGLE 112(1)CBE DATE 23.01.2008.

122 Ep: pct application non-entry in european phase

Ref document number: 04793741

Country of ref document: EP

Kind code of ref document: A2